Домваналимаб

Rec. INN (наименование, зарегистрированное ВОЗ)

2368219-35-4

immunoglobulin G1-kappa, anti-[Homo sapiens TIGIT (T-cell immunoreceptor with Ig domain and ITIM, V-set Ig member 9, VSIG9, V-set and transmembrane member 3, VSTM3)], humanized monoclonal antibody;
gamma1 heavy chain humanized (1-448) [VH (Homo sapiens IGHV3-48*01 (90.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.12] (26-33.51-58.97-108) (1-119) -Homo sapiens IGHG1*01, G1m17,1, G1v14 CH2 A1.3, A1.2 (CH1 K120 (216) (120-217), hinge 1-15 (218-232), CH2 L1.3>A (236), L1.2>A (237) (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K>del (448)) (120-448)], (222-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-16*01 (89.5%) -IGKJ4*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (228-228'':231-231'')-bisdisulfide, produced in a Chinese hamster ovary (CHO)-K1 cell line, glycoform alfa

Поделиться этой страницей